Application of saussurea involucrata and fructus hippophae polysaccharide in inhibiting emotional disorder response induced by long-term exposure of low-dose ion radiation
By using syrupin and sea buckthorn fruit polysaccharide as drug components, the problem of emotional disorder response caused by low-dose ion radiation is solved, especially anxiety and depression emotional response, effective prevention and treatment is achieved, and new protection strategies and research directions are provided. .
Patent Information
- Application Number
- CN202411173375.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-15
AI Technical Summary
The emotional disorder responses caused by long-term exposure to low-dose ion radiation, especially anxiety and depression, are currently lacking effective protective strategies and limited research data.
Using serolin and sea buckthorn fructose as pharmaceutical ingredients, the prevention and treatment of low-dose ionizing radiation-induced emotional disorder responses, including anxiety and depression, can include serolin and sea buckthorn. Frupolysaccharide and pharmaceutically acceptable excipients, dosage forms and administration methods are diverse, and are suitable for different individuals.
Through animal experiments, schnopsis and sea buckthorn fructose can effectively antagonize the anxiety and depression emotional response induced by low-dose ion radiation, providing safe and efficient prevention and treatment plans, and have broad application prospects.
Smart Images

Figure CN118948920A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and in particular, the present invention relates to the application of yaconin and seabuckthorn fruit polysaccharide in inhibiting mood disorder reactions induced by long-term exposure to low-dose ionizing radiation. Background Art
[0002] Low-dose ionizing radiation (LDIR) refers to radiation with a dose of less than 0.1 Gy. Unlike high-dose ionizing radiation (HDIR), LDIR exposure is usually unavoidable (such as medical radiography, adverse reactions to tumor radiotherapy, air diffusion after nuclear accidents, nuclear submarines, etc.), but the injury effect is not completely clear. Therefore, the health hazards caused by long-term exposure to LDIR are currently the focus and difficulty of research in the field of radiation biology and radiation medicine. Since the results of human epidemiological studies on this topic are somewhat difficult to make accurate judgments, there is still a lot of controversy in the scientific community about whether LDIR exposure has beneficial or harmful effects on human health. The reasons for these differences in results are related to factors such as the genetic background, age, gender, radiation exposure method, radiation source and radionuclide composition of the subjects, and the design of human epidemiological experiments. In particular, in the study of changes in brain cognitive function caused by LDIR, accurate research data on long-term health hazards are extremely limited. Therefore, it is crucial to explore the effects of LDIR on brain cognitive function, clarify key scientific issues in the field of radiation biology and radiation medicine research, and find corresponding protection strategies.
[0003] Snow lotus is a traditional medicinal plant, and its most common use is to treat inflammation. In recent years, it has been shown to have positive effects such as anti-cancer, antioxidant, anti-aging, neuroprotection and anti-hypoxia. The main components of snow lotus include chlorogenic acid and rutin. Saussurea Involucrata (SI) is extracted from snow lotus, and its ingredients include a variety of compounds (such as flavonoids, lignans, coumarins, etc.). At present, saussurea is mainly used for skin care and maintenance of female reproductive health. Whether it has a protective effect in ion radiation reactions has not been reported.
[0004] Seabuckthorn is a traditional Chinese medicine with a long history of clinical application. It has been used in traditional Chinese medicine to improve and treat a variety of diseases such as strengthening the stomach and digestion, relieving cough and reducing phlegm, and promoting blood circulation and removing blood stasis. Seabuckthorn fruit polysaccharide (Hippophae Rhamnoides L. Polysaccharides, HLP) is an important active substance in seabuckthorn. Studies have shown that seabuckthorn fruit polysaccharide has multiple effects such as anti-inflammatory, antioxidant, and anti-cancer, as well as liver and neuroprotective activities. In recent years, seabuckthorn fruit polysaccharide has attracted widespread attention from brain scientists for its unique effect in improving Alzheimer's disease (AD). It has been reported that seabuckthorn fruit polysaccharide improves the inflammatory response caused by D-gal and AlCl by inhibiting oxidative stress and inflammatory response.3 Cognitive dysfunction in AD mice induced by combined treatment. At present, whether seabuckthorn fruit polysaccharides have a protective effect on brain damage response induced by ionizing radiation has not been reported. Summary of the invention
[0005] The purpose of the present invention is to provide the use of yaconin and seabuckthorn fruit polysaccharide in inhibiting emotional disorder reactions induced by long-term exposure to low-dose ionizing radiation. The present invention is the first to discover that preventive administration of yaconin and seabuckthorn fruit polysaccharide can inhibit negative emotional reactions induced by long-term exposure to LDIR, providing a clear plan for medical protection against brain damage reactions induced by long-term LDIR exposure.
[0006] The above-mentioned purpose of the present invention is achieved through the following technical solutions:
[0007] The first aspect of the present invention provides the use of yaconin and / or seabuckthorn fruit polysaccharide in the preparation of a medicament for preventing and / or treating mood disorders induced by low-dose ionizing radiation.
[0008] Furthermore, the emotional disorder reaction induced by ionizing radiation includes anxiety and / or depression emotional reaction induced by ionizing radiation.
[0009] Furthermore, the medicine comprises a preventive and / or therapeutically effective amount of yaconin and / or seabuckthorn fruit polysaccharide.
[0010] Furthermore, the drug further comprises a pharmaceutically acceptable excipient;
[0011] Optionally, the pharmaceutically acceptable excipients include surfactants, diluents, wetting agents, binders, fillers, adsorption carriers, lubricants and / or disintegrants;
[0012] Optionally, the dosage form of the drug includes solution, tablet, capsule, granule, ointment, suppository, inhalant, gel, microsphere and / or aerosol.
[0013] Furthermore, the administration of the drug includes oral administration, subcutaneous injection, intramuscular injection, intravenous injection and / or intraperitoneal injection.
[0014] In the present invention, the low-dose irradiation (LDIR) refers to radiation with a dose of less than 0.1 Gy. The present invention has verified through animal experiments that long-term exposure to LDIR can induce emotional disorders, including anxiety and depression.
[0015] In some embodiments, the ionizing radiation includes, but is not limited to, gamma ray irradiation, alpha ray irradiation, beta ray irradiation, X-ray irradiation, neutron irradiation, and / or any combination thereof.
[0016] In a specific embodiment of the present invention, the ionizing radiation is gamma irradiation.
[0017] A second aspect of the present invention provides a pharmaceutical composition for preventing and / or treating mood disorder reactions induced by low-dose ionizing radiation.
[0018] Furthermore, the pharmaceutical composition comprises a preventive and / or therapeutically effective amount of yaconin and / or seabuckthorn fruit polysaccharide.
[0019] Furthermore, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient;
[0020] Optionally, the pharmaceutically acceptable excipients include surfactants, diluents, wetting agents, binders, fillers, adsorption carriers, lubricants and / or disintegrants;
[0021] Optionally, the ionizing radiation-induced mood disorder reaction includes ionizing radiation-induced anxiety and / or depression mood reactions.
[0022] In some embodiments, the pharmaceutical composition may also contain other compounds that can be used to prevent and / or treat mood disorders induced by low-dose ionizing radiation, that is, the yaconin and / or seabuckthorn fruit polysaccharide can be administered together with other compounds that can be used to prevent and / or treat mood disorders induced by low-dose ionizing radiation.
[0023] In some embodiments, the other compounds that can be used to prevent and / or treat mood disorders induced by low-dose ionizing radiation include but are not limited to: sulfhydryl compounds, hormone drugs, Chinese herbal medicines, cytokines, vitamins, anti-anxiety or anti-depressant drugs, etc.
[0024] In some embodiments, the aminothiol compound includes but is not limited to: amifostine (WR2721), cystamine, cysteamine, β-mercaptoethylamine, aminoalkyl thiosulfate, aminoalkyl dithiophosphate, etc. The hormone drugs include but are not limited to: estradiol, estrogen, androgen, hexane estradiol, diethylstilbestrol, nilestriol, etc. The Chinese herbal medicine includes but is not limited to: anthocyanidins, flavonoids, isothiocyanates, bioflavonoid epigallocatechin gallate, luteolin, quercetin, kaempferol, apigenin, taxifolin, etc. The cytokines include but are not limited to: granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), erythropoietin (EPO), interleukin I (IL-I), interleukin II (IL-II), stem cell factor (SCF), etc. The vitamins include but are not limited to: vitamin A, vitamin C, vitamin E, etc. The anti-anxiety or anti-depressant drugs include, but are not limited to, escitalopram (Lexapro), duloxetine (Cymbalta), venlafaxine (Effexor XR), paroxetine (Paxil, Pexeva), buspirone, and the like.
[0025] In some embodiments, the administration methods of the drug include but are not limited to: subcutaneous injection, intramuscular injection, intravenous injection, oral administration, rectal administration, nasal administration, transdermal administration, subconjunctival administration, intraocular administration, orbital administration, retro-ocular administration, retinal administration, choroidal administration, intrathecal injection, intraperitoneal injection, etc.
[0026] Those skilled in the art will understand that the effective amount and specific treatment regimen for a certain subject (such as a mammal: a human) for prevention and / or treatment may be affected by many factors, including the pharmacodynamic activity of the compound used, the age, weight, general condition, gender, diet, administration time, disease susceptibility, disease progression, and the judgment of the corresponding physician, etc. In addition, those skilled in the art will understand that the administration method, dosage form, and dosage of the drug are affected by many factors such as the patient's age, gender, and morbidity. Therefore, the administration method, dosage form, and dosage of the drug or drug composition or drug preparation described in the present invention are not limited to the administration method, dosage form, and dosage listed in the present invention. The administration method, dosage form, and dosage that can produce a certain above-mentioned prevention and / or treatment effect on a subject in need all fall within the scope of protection of the present invention.
[0027] A third aspect of the present invention provides a pharmaceutical preparation for preventing and / or treating mood disorder reactions induced by low-dose ionizing radiation.
[0028] Furthermore, the pharmaceutical preparation comprises the pharmaceutical composition described in the second aspect of the present invention.
[0029] Furthermore, the dosage form of the pharmaceutical preparation includes a dosage form for enteral administration and a dosage form for parenteral administration;
[0030] Optionally, the dosage form for administration through the gastrointestinal tract includes solutions, granules, tablets, capsules, suspensions, powders, sustained-release preparations, effervescent preparations, emulsions, syrups, drops and / or chewable preparations;
[0031] Optionally, the non-gastrointestinal administration dosage form includes an injection dosage form, a respiratory tract administration dosage form, a cavity administration dosage form, a mucosal administration dosage form and / or a skin administration dosage form;
[0032] Optionally, the ionizing radiation-induced mood disorder reaction includes ionizing radiation-induced anxiety and / or depression mood reactions.
[0033] In the present invention, the dosage form of the drug, pharmaceutical composition or pharmaceutical preparation is not particularly limited. In some embodiments, the drug, pharmaceutical composition or pharmaceutical preparation can be prepared into an injection or oral preparation, including injection, tablet, capsule, pill, suppository, aerosol, oral liquid preparation, granule, powder, sustained release agent, nano preparation, syrup, wine, tincture, dew. Those skilled in the art can select a suitable dosage form known in the art according to actual needs (e.g., improving the bioavailability of the drug, improving the patient's medication compliance, etc.).
[0034] In the present invention, the effective preventive and / or therapeutic dose of the drug, drug composition or drug preparation can be prescribed in a variety of ways based on the actual formulation method, administration method, patient's age, weight, gender, morbidity, diet, administration time, administration route, excretion rate and reaction sensitivity, and a skilled physician can usually easily determine the prescription and the dosage that is effective for the desired prevention and / or treatment.
[0035] A fourth aspect of the present invention provides any of the following applications:
[0036] (1) Use of yaconin and / or seabuckthorn fruit polysaccharide in the preparation of a pharmaceutical composition or pharmaceutical preparation for preventing and / or treating mood disorders induced by low-dose ionizing radiation;
[0037] (2) Use of yaconin and / or seabuckthorn fruit polysaccharide in the preparation of food, food additives, cosmetics and / or health products for preventing and / or treating mood disorders induced by low-dose ionizing radiation.
[0038] In some embodiments, the food for preventing and / or treating mood disorders induced by low-dose ionizing radiation comprises a preventive and / or therapeutically effective amount of yaconin and / or seabuckthorn fruit polysaccharide.
[0039] In some embodiments, the food for preventing and / or treating mood disorders induced by low-dose ionizing radiation may also contain other substances with anti-radiation effects. Exemplarily, the substances include but are not limited to: spirulina, pomegranate seeds, grape seeds, kelp, seaweed, tomato, rhodiola rosea, red raspberries, blackberries, mulberries, wolfberries, etc.
[0040] In some embodiments, the food additive for preventing and / or treating mood disorder reactions induced by low-dose ionizing radiation comprises a preventive and / or therapeutically effective amount of yaconin and / or seabuckthorn fruit polysaccharide.
[0041] In some embodiments, the food additives for preventing and / or treating mood disorders induced by low-dose ionizing radiation may also include other food additives with anti-radiation effects. Exemplarily, the food additives include but are not limited to: soy protein low-molecular peptides, grape proanthocyanidins, Ganoderma lucidum polysaccharides, etc.
[0042] In some embodiments, the cosmetic for preventing and / or treating mood disorders induced by low-dose ionizing radiation comprises a preventive and / or therapeutically effective amount of yaconin and / or seabuckthorn fruit polysaccharide.
[0043] In some embodiments, the cosmetics for preventing and / or treating mood disorder reactions induced by low-dose ionizing radiation may also include preservatives, moisturizers, viscosity controllers, softeners, thickeners, desiccants, detergents, lubricants, and the like.
[0044] In some embodiments, the preservatives include but are not limited to: phenoxyethanol, methylparaben, ethylparaben, propylparaben, butylparaben, isopropylparaben, isobutylparaben, 1,3-dihydroxymethyl-5,5-dimethylhydantoin (DMDMH), imidazolidinyl urea, diazolidinyl urea, quaternary ammonium salt-15 (DOW ICILTM 200), sodium hydroxymethylglycinate, methylchloroisothiazolinone, methylisothiazolinone, iodopropynyl butylcarbamate, etc.
[0045] In some embodiments, the moisturizer includes but is not limited to: ceramide, hyaluronic acid, lactic acid, allantoin, niacinamide, glycerin, propylene glycol, 1,3-butylene glycol, sorbitol, polyethylene glycol, petrolatum, polydimethylsiloxane (250-5000cSt), lanolin and its derivatives, plant fats / oils and their derivatives, high relative molecular mass linear fatty acid esters, cetyl palmitate, film-forming polymers, etc.
[0046] In some embodiments, the health product for preventing and / or treating mood disorders induced by low-dose ionizing radiation comprises a preventive and / or therapeutically effective amount of yaconin and / or seabuckthorn fruit polysaccharide.
[0047] In some embodiments, the health care products for preventing and / or treating mood disorders induced by low-dose ionizing radiation may also contain other substances with anti-radiation effects. For example, the substances include but are not limited to: spirulina, pomegranate seeds, grape seeds, kelp, seaweed, tomato, rhodiola rosea, red raspberries, blackberries, mulberries, wolfberries, etc.
[0048] The present invention also provides food, food additives, cosmetics and / or health products for preventing and / or treating mood disorders induced by low-dose ionizing radiation, wherein the food, food additives, cosmetics and / or health products contain a preventive and / or therapeutically effective amount of yaconin and / or seabuckthorn fruit polysaccharide.
[0049] The present invention also provides a method for preventing and / or treating mood disorder reactions induced by low-dose ionizing radiation, the method comprising administering a preventive and / or therapeutically effective amount of the drug, pharmaceutical composition or pharmaceutical preparation of the present invention as described above to a subject in need.
[0050] In some embodiments, the method for preventing mood disorder reactions induced by low-dose ionizing radiation comprises administering an effective amount of yaconin and / or seabuckthorn fruit polysaccharide, the drug, pharmaceutical composition or pharmaceutical preparation as described above of the present invention to a subject in need thereof within a few days or at least a few hours before (possibly) low-dose ionizing radiation exposure.
[0051] In some embodiments, an effective amount of yaconin and / or sea buckthorn fruit polysaccharide, the drug, pharmaceutical composition or pharmaceutical preparation as described above of the present invention is continuously administered several times (for example: 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, etc.) 2 days, 1 day, or 3 hours before (possible) exposure to low-dose ionizing radiation.
[0052] In some embodiments, the dosage of yaconin and / or seabuckthorn fruit polysaccharide is 20 mg / kg-6000 mg / kg.
[0053] In some embodiments, the method for treating mood disorder reactions induced by low-dose ionizing radiation comprises administering an effective amount of yaconin and / or seabuckthorn fruit polysaccharide, the drug, pharmaceutical composition or pharmaceutical preparation as described above of the present invention to a subject in need (a subject exposed to low-dose ionizing radiation).
[0054] In some embodiments, an effective amount of yaconin and / or seabuckthorn fruit polysaccharide, the medicament, pharmaceutical composition or pharmaceutical preparation as described above of the present invention is administered within days or hours after exposure to low-dose ionizing radiation.
[0055] In some embodiments, an effective amount of yaconin and / or seabuckthorn fruit polysaccharide, the drug, pharmaceutical composition or pharmaceutical preparation as described above of the present invention is continuously administered several times (for example: 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, etc.) 2 hours, 3 hours, 1 day, 2 days, or 3 days after exposure to low-dose ionizing radiation.
[0056] In some embodiments, the dosage of yaconin and / or seabuckthorn fruit polysaccharide is 20 mg / kg-6000 mg / kg.
[0057] In the present invention, there is no particular restriction on the dosage of the yaconin and / or seabuckthorn fruit polysaccharide. Optionally, the dosage of the yaconin and / or seabuckthorn fruit polysaccharide is 20 mg / kg-6000 mg / kg. Any dosage within the above range or any dosage that can produce a certain preventive or therapeutic effect on the subject is within the protection scope of the present invention.
[0058] In some embodiments, the subject includes mammals and non-mammals, and in other embodiments, the subject is preferably a human, including subjects who may be exposed to low-dose ionizing radiation for a long time, subjects who are at risk of long-term exposure to low-dose ionizing radiation, and subjects who are exposed to low-dose ionizing radiation for a long time.
[0059] Compared with the prior art, the present invention has the following advantages and beneficial effects:
[0060] The present invention discovers for the first time and confirms through animal experiments that pretreatment with yaconin and seabuckthorn fruit polysaccharide can antagonize LDIR-induced anxiety and depression reactions. Both yaconin and seabuckthorn fruit polysaccharide are natural plant ingredients, and have the advantages of low toxicity, high safety, high effectiveness, etc. In addition, the raw material resources of yaconin and seabuckthorn fruit polysaccharide are abundant, and have good social and economic benefits. The present invention provides a new idea and strategy for the research and development of preventive and / or therapeutic drugs for LDIR-induced anxiety and depression reactions, and has broad application prospects in the field of prevention and / or treatment of LDIR-induced anxiety and depression reactions. BRIEF DESCRIPTION OF THE DRAWINGS
[0061] Figure 1 These are the results of anxiety-like emotions induced by long-term exposure to LDIR in mice (elevated plus maze test), where Figure A: elevated plus maze test result diagram, Figure B: elevated plus maze test result statistical diagram;
[0062] Figure 2 This is the result diagram corresponding to the depression-like mood induced by long-term exposure to LDIR in mice (forced swimming test);
[0063] Figure 3These are the result graphs corresponding to the fact that pretreatment with yaconin and seabuckthorn fruit polysaccharide can antagonize LDIR-induced anxiety and depression reactions, wherein, Figure A: elevated plus maze test result graph, Figure B: elevated plus maze test result statistical graph, Figure C: forced swimming test result graph, wherein SI refers to yaconin, and HLP refers to seabuckthorn fruit polysaccharide. DETAILED DESCRIPTION
[0064] After extensive and in-depth research, the inventors of the present invention have found for the first time that yaconin and seabuckthorn fruit polysaccharide pretreatment can be used to effectively antagonize LDIR-induced anxiety and depression reactions, and have good potential for development into LDIR-induced anxiety and depression prevention and / or treatment drugs. In order to facilitate the understanding of the present invention, some of the terms involved in the present invention are explained as follows:
[0065] As used herein, the term "LDIR", also known as low-dose irradiation (LDIR), refers to radiation with a dose of less than 0.1Gy. Long-term exposure to LDIR may cause health effects including cancer and non-cancerous diseases. Currently, epidemiological studies related to LDIR are subject to many uncertainties. The present invention has verified through animal experiments that long-term exposure to LDIR can induce emotional disorders, including anxiety and depression.
[0066] As used in this article, the term "saustraxin" is extracted from snow lotus, and its ingredients include a variety of compounds (such as flavonoids, lignans, coumarins, etc.). Currently, saustraxin is mainly used for skin care and maintenance of female reproductive health. Whether it has a protective effect in ion radiation reactions has not been reported.
[0067] In some embodiments, the yaconin includes yaconin or its derivatives, and the derivatives include pharmaceutically acceptable salts, hydrates, enantiomers, diastereomers, solvates or crystalline forms corresponding to various compounds contained in yaconin.
[0068] As used in this article, the term "sea buckthorn fruit polysaccharide" is an important active substance in sea buckthorn. Studies have shown that sea buckthorn fruit polysaccharide has multiple effects such as anti-inflammatory, antioxidant, anti-cancer, and liver and neuroprotective activities. At present, whether sea buckthorn fruit polysaccharide has a protective effect in brain damage response induced by ionizing radiation has not been reported.
[0069] In some embodiments, the seabuckthorn fruit polysaccharide includes seabuckthorn fruit polysaccharide or its derivatives, and the derivatives include pharmaceutically acceptable salts, hydrates, enantiomers, diastereomers, solvates or crystalline forms corresponding to various compounds contained in seabuckthorn fruit polysaccharide.
[0070] As used herein, the term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable salt of a specified compound in yaconin or seabuckthorn fruit polysaccharide, which means a carboxylate, an amino acid addition salt, etc. of the compound, which are suitable for contact with patients within the scope of reliable medical judgment, do not produce undue toxicity, irritation, allergic reactions, etc., are commensurate with a reasonable benefit / risk ratio, and are effective for their intended use, including (if possible) the zwitterionic form of the above-mentioned compounds.
[0071] In some embodiments, the salt can be a sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide prepared from an inorganic acid, such as hydrochloric acid, nitric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, etc. Representative salts include: hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, toluenesulfonate, citrate, maleate, fumarate, succinate, tartrate, naphthoate, methanesulfonate, glucoheptonate, lactobionate, lauryl sulfonate, and isethionate, etc. Salts can also be prepared from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Representative salts include acetate, propionate, octanoate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, naphthoate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, etc. Pharmaceutically acceptable salts may include cations based on alkali metals and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, etc., as well as non-toxic ammonium, quaternary ammonium and amine cations, including but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, etc. Also contemplated are salts of amino acids, such as arginate, gluconate, galacturonate, etc.
[0072] As used herein, the term "prevention and / or treatment" refers to the medical management of a patient for the purpose of preventing, curing, ameliorating or stabilizing a disease, pathological condition or condition. The term includes active therapy, i.e., treatment specifically for the purpose of ameliorating a disease, pathological condition or condition, and also includes etiological treatment, i.e., treatment for the purpose of removing the cause of the disease, pathological condition or condition in question.
[0073] In addition, the term "prevention and / or treatment" also includes palliative treatment, i.e., treatment designed to relieve symptoms rather than cure a disease, pathological state or condition; the term also includes preventive treatment, i.e., treatment aimed at minimizing or partially or completely inhibiting the development of the relevant disease, pathological state or condition; and supportive treatment, i.e., treatment used to supplement another specific therapy aimed at improving the relevant disease, pathological state or condition. In a specific embodiment of the present invention, the disease refers in particular to LDIR-induced anxiety and depressive mood reactions.
[0074] As used herein, the term "effective amount" refers to an amount with a preventive and / or therapeutic effect or an amount required to produce a preventive and / or therapeutic effect in a subject. For example, a pharmaceutically preventive and / or therapeutically effective amount refers to the amount of a drug required to produce the desired preventive and / or therapeutic effect, and the preventive and / or therapeutic effect can be reflected by the results of clinical trial results, model animal studies, and / or in vitro studies. The pharmaceutically effective amount depends on several factors, including but not limited to: characteristic factors of the subject (such as height, weight, sex, age, and medication history), and the severity of the disease.
[0075] In some embodiments, the preventive effective amount refers to an amount sufficient to prevent a disease, disorder or condition, or an amount sufficient to prevent one or more symptoms associated with a disease, disorder or condition, or an amount to prevent the recurrence of a disease, disorder or condition. The preventive effective amount of a compound refers to an amount of a therapeutic agent when used alone or in combination with other agents, which provides a preventive benefit in the process of preventing a disease, disorder or condition. The preventive effective amount may include an amount that improves overall prevention, or an amount that enhances the preventive effect of other preventive agents.
[0076] In some embodiments, the therapeutically effective amount refers to an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder, or condition, or to delay or minimize one or more symptoms associated with the disease, disorder, or condition. A therapeutically effective amount of a compound refers to an amount of a therapeutic agent that provides a therapeutic benefit in the treatment of a disease, disorder, or condition, either alone or in combination with other therapies. A therapeutically effective amount includes an amount that improves overall treatment, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic effect of other therapeutic agents.
[0077] As used herein, the term "pharmaceutically acceptable excipient" is described in detail in Remington's Pharmaceutical Sciences (19th ed, 1995). The "pharmaceutically acceptable excipient" is used as needed to help the stability of the pharmaceutical composition or pharmaceutical preparation or to help improve the activity of the effective active ingredients in the pharmaceutical composition or pharmaceutical preparation (in the present invention, especially yaconin and / or seabuckthorn fruit polysaccharides). The active ingredients that can be used in such pharmaceutical compositions or pharmaceutical preparations can be in the form of their original compounds themselves, or optionally in the form of pharmaceutically acceptable salts thereof. The pharmaceutical compositions or pharmaceutical preparations formulated in this way can be administered to subjects or test subjects in need by any appropriate method known to those skilled in the art as needed.
[0078] In addition, the "pharmaceutically acceptable excipients" may additionally contain liquids such as water, saline, glycerol and ethanol. In addition, auxiliary substances such as wetting agents or emulsifiers or pH buffer substances may be present in the composition. These excipients enable the pharmaceutical composition or pharmaceutical preparation to be formulated into tablets, pills, dragees, capsules, liquids, gels, syrups, slurries and suspensions for patient ingestion.
[0079] In one embodiment, examples of pharmaceutically acceptable excipients of the present invention include, but are not limited to, preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavoring agents, salts for regulating osmotic pressure, buffers, masking agents or antioxidants. In addition, by including ingredients that delay absorption, the pharmaceutical dosage form can be prolonged for absorption.
[0080] In some embodiments, the pharmaceutical composition or pharmaceutical preparation described in the present invention can be prepared into a dosage form suitable for oral administration, parenteral administration or topical administration by a known method, such as by conventional mixing, granulation, coating, solvent or freeze-drying methods, and the dosage form includes but is not limited to: tablets, capsules, granules, injections, powders for injection, transdermal patches, ointments, gels, suppositories, oral solutions, oral suspensions, emulsions for injection, oral emulsions, sustained-release tablets, controlled-release tablets, etc.
[0081] In some embodiments, the pharmaceutical composition or pharmaceutical preparation described in the present invention can be conveniently present in unit dosage form and can be prepared by any pharmaceutical method well known in the pharmaceutical field. The amount of active ingredient that can be combined with excipients to produce a single dosage form will vary depending on the subject being treated and the specific mode of administration. The amount of active ingredient that can be combined with excipients to produce a single dosage form is generally the amount of terminalia chebula tannic acid that produces a therapeutic effect. Typically, out of 100%, the amount will range from about 1% to about 90% of the active ingredient, preferably from about 5% to about 70%, and most preferably from about 10% to about 30%.
[0082] When using the pharmaceutical composition or pharmaceutical preparation provided by the present invention, its administration regimen and dosage regimen can be selected according to a variety of factors, including the type, species, age, weight, sex, type of disease or symptom to be prevented or treated; severity of the disease or symptom to be prevented or treated; route of administration; renal and liver function of the patient; and the specific compound or salt thereof used. A dosing / dosage regimen can be used, for example, to prevent a disease, inhibit (completely or partially) a disease, or stop the development of the disease.
[0083] As used herein, the term "administering" refers to contact of an exogenous drug, pharmaceutical composition, or pharmaceutical formulation with an animal, human, subject, cell, tissue, organ, or biological fluid when applied to the subject. "Administering" may refer to, for example, prevention, treatment, pharmacokinetics, diagnosis, research, and experimental methods. Treatment of cells includes contact of an agent with a cell, and contact of an agent with a fluid. "Administering" also means treating a cell in vitro and ex vivo by an agent, composition, or by another cell, and when the "treatment" is applied to a human, veterinary, or research subject, it refers to therapeutic treatment, prevention or preventive measures, research, and diagnostic applications.
[0084] As used herein, the term "subject" refers to any animal, including humans and non-human animals. The term "non-human animal" includes all vertebrates, for example, mammals, such as non-human primates (particularly higher primates), sheep, dogs, rodents (such as mice or rats), guinea pigs, goats, pigs, cats, rabbits, cows, and any livestock or pets; and non-mammals, such as chickens, amphibians, reptiles, etc. In a specific embodiment of the present invention, the subject is preferably a human.
[0085] In some embodiments, the subject is a human, including a subject that may be chronically exposed to low-dose ionizing radiation, a subject that is at risk of chronically exposed to low-dose ionizing radiation, and a subject that is chronically exposed to low-dose ionizing radiation.
[0086] In some embodiments, the drug, pharmaceutical composition or pharmaceutical preparation of the present invention as described above can be administered to a subject in need thereof by oral administration, injection or topical administration. For example, the method can include administering the drug, pharmaceutical composition or pharmaceutical preparation to a subject in need thereof three times a day, once a day, once every two days, etc. In some embodiments, injection administration can include subcutaneous injection, intramuscular injection, intravenous injection, etc. In some embodiments, a combination of different administration methods can be used.
[0087] The present invention is further described below in conjunction with specific embodiments, which are only used to explain the present invention and cannot be understood as limiting the present invention. Those skilled in the art can understand that: various changes, modifications, substitutions and variations can be made to these embodiments without departing from the principles and purpose of the present invention, and the scope of the present invention is defined by the claims and their equivalents.
[0088] The drugs, reagents and raw materials used in the present invention are easily obtained by ordinary technicians in the field and can be obtained from commercial channels unless otherwise specified. The experimental methods in the present invention that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. In particular, the following examples are only used to illustrate the present invention and should not limit the scope of the present invention in any way.
[0089] Example Pretreatment with yaconin and seabuckthorn fruit polysaccharide can antagonize LDIR-induced anxiety and depression 1. Experimental methods
[0090] (1) Animal model construction: 8-week-old male mice were exposed to 0.01 Gy of 60Co γ-rays, once every other day for 10 consecutive times, with a total irradiation dose of 0.1 Gy. Animal behavioral experiments were performed 30 days after irradiation. Anxiety-like emotions were detected by the elevated plus maze test, and depression-like emotions were detected by the forced swimming test.
[0091] (2) Analysis of yaconin pretreatment and its effects: 16 h before each LDIR exposure, yaconin (purchased from Shanxi Kangbao Biotechnology Co., Ltd.) was administered intragastrically at a dose of 2.5 g / kg for 10 consecutive times, once before each irradiation. The same behavioral methods mentioned above were used to detect the effect of yaconin on LDIR-induced emotional changes.
[0092] (3) Analysis of pretreatment and effect of seabuckthorn polysaccharide: Seabuckthorn polysaccharide extract (kindly donated by Professor Zhao Hong of the School of Pharmacy of Jiamusi University) was administered intragastrically 16 h before each LDIR exposure at a dose of 75 mg / kg for 10 consecutive times, once before each irradiation. The same behavioral method mentioned above was used to detect the effect of seabuckthorn polysaccharide on LDIR-induced emotional changes.
[0093] 2. Experimental results
[0094] (1) Long-term exposure to LDIR induces anxiety-like emotions in mice
[0095] After 10 intermittent LDIR exposures, mice were tested on the elevated plus maze 30 days later. The results showed that the exposure group mice entered the closed arm significantly longer than the control group mice, and the reaction persisted for a long time (up to 30 days after exposure) (*p<0.05) ( Figure 1 ), suggesting that long-term LDIR can induce anxiety-like emotions in model animals.
[0096] (2) Long-term exposure to LDIR induces depression-like mood in mice
[0097] The mice were subjected to a forced swimming test on the 30th day after 10 intermittent LDIR exposures. The results showed that the mice in the exposed group remained immobile in the water for a significantly longer time than the mice in the control group, and the reaction persisted for a long time (up to 30 days after exposure) (**p<0.01) ( Figure 2 ), suggesting that long-term LDIR can induce depression-like emotions in model animals.
[0098] (3) Pretreatment with yaconin and seabuckthorn fruit polysaccharide can antagonize LDIR-induced anxiety and depression
[0099] To investigate whether yaconin and seabuckthorn fruit polysaccharide have a protective effect on LDIR-induced brain injury, we pretreated mice with yaconin and seabuckthorn fruit polysaccharide and then subjected them to long-term LDIR exposure. The results showed that 30 days after exposure, yaconin and seabuckthorn fruit polysaccharide pretreatment significantly inhibited the prolonged closed arm entry time of mice in the elevated plus maze ( Figure 3 AB), and the prolonged immobility time in the forced swimming test was also effectively alleviated ( Figure 3 C). The above results indicate that yaconin and seabuckthorn fruit polysaccharide can play an important role in antagonizing the anxiety and depression induced by long-term exposure to LDIR.
[0100] The description of the above embodiments is only used to understand the method and core idea of the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.
Claims
1. Use of yaconin and / or seabuckthorn fruit polysaccharide in the preparation of a drug for preventing and / or treating mood disorders induced by low-dose ionizing radiation.
2. The use according to claim 1, characterized in that: The mood disorder reactions induced by ionizing radiation include anxiety and / or depression mood reactions induced by ionizing radiation.
3. The use according to claim 1, characterized in that: The medicine comprises a preventive and / or therapeutically effective amount of yaconin and / or seabuckthorn fruit polysaccharide.
4. The use according to claim 1, characterized in that: The drug further comprises a pharmaceutically acceptable excipient; Optionally, the pharmaceutically acceptable excipients include surfactants, diluents, wetting agents, binders, fillers, adsorption carriers, lubricants and / or disintegrants; Optionally, the dosage form of the drug includes solution, tablet, capsule, granule, ointment, suppository, inhalant, gel, microsphere and / or aerosol.
5. The use according to claim 1, characterized in that: The administration of the drug includes oral administration, subcutaneous injection, intramuscular injection, intravenous injection and / or intraperitoneal injection.
6. A pharmaceutical composition for preventing and / or treating mood disorders induced by low-dose ionizing radiation, characterized in that: The pharmaceutical composition comprises a preventive and / or therapeutically effective amount of yaconin and / or seabuckthorn fruit polysaccharide.
7. The pharmaceutical composition according to claim 6, characterized in that The pharmaceutical composition further comprises a pharmaceutically acceptable excipient; Optionally, the pharmaceutically acceptable excipients include surfactants, diluents, wetting agents, binders, fillers, adsorption carriers, lubricants and / or disintegrants; Optionally, the ionizing radiation-induced mood disorder reaction includes ionizing radiation-induced anxiety and / or depression mood reactions.
8. A pharmaceutical preparation for preventing and / or treating mood disorders induced by low-dose ionizing radiation, characterized in that: The pharmaceutical preparation comprises the pharmaceutical composition according to claim 6 or 7.
9. The pharmaceutical preparation according to claim 8, characterized in that The dosage forms of the pharmaceutical preparation include enteral administration dosage forms and parenteral administration dosage forms; Optionally, the dosage form for administration through the gastrointestinal tract includes solutions, granules, tablets, capsules, suspensions, powders, sustained-release preparations, effervescent preparations, emulsions, syrups, drops and / or chewable preparations; Optionally, the non-gastrointestinal administration dosage form includes an injection dosage form, a respiratory tract administration dosage form, a cavity administration dosage form, a mucosal administration dosage form and / or a skin administration dosage form; Optionally, the ionizing radiation-induced mood disorder reaction includes ionizing radiation-induced anxiety and / or depression mood reactions.
10. Any one of the following applications, characterized in that: The applications include: (1) Use of yaconin and / or seabuckthorn fruit polysaccharide in the preparation of a pharmaceutical composition or pharmaceutical preparation for preventing and / or treating mood disorders induced by low-dose ionizing radiation; (2) Use of yaconin and / or seabuckthorn fruit polysaccharide in the preparation of food, food additives, cosmetics and / or health products for preventing and / or treating mood disorders induced by low-dose ionizing radiation.
Citation Information
Patent Citations
Pure natural plant essence perfume with anti-depression and anti-anxiety functions
CN109793870A
Low-GI sea-buckthorn functional biscuit capable of relieving depression and anxiety
CN115989823A
